New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine
In a recent interview, Cathy Cutler, Ph.D., shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging.
A longtime researcher who has over two decades of experience in the development and assessment of radiopharmaceuticals, Cathy Cutler, Ph.D., said she is excited about the increased patient interest in positron emission tomography (PET).
“We’re at a point where patients know so much more about PET and they’re asking for this. They want to ensure their doctors have these tools to better inform their therapies. It’s exciting to see that. When you talk to patients, they’re out there now fighting with us to help make sure they have access to PET imaging, It’s not where I thought we would be about 20 years ago but it’s very exciting to see that is where we are today,” noted Dr. Cutler, the new president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Dr. Cutler said it’s important to build upon that enthusiasm in recruiting talented people into the field. Through recent surveys conducted through the SNMMI’s workforce pipeline, Dr. Cutler noted significant numbers of pending retirees so there is increasing urgency to ramp up recruiting efforts. Noting a visit to a local high school in Toronto by SNMMI leaders during the conference, Dr. Cutler said video testimonials from physicians, scientists, and technologists about the benefits of the field are also being shared with younger audiences to help spark interest.
As the director of the Medical Isotope Research Production and Development Group at Brookhaven National Laboratory in New York. Dr. Cutler said isotope availability is an ongoing challenge with demand likely to increase as more radiopharmaceuticals are utilized in patient treatment. Appropriate reimbursement is another challenge in the field, according to Dr. Cutler.
“Unfortunately, the CMS … looks at diagnostic radiopharmaceuticals as supplies, kind of like gloves so they basically bundle the costs,” posted Dr. Cutler. “It turns out those costs really don’t cover what it takes us to manufacture those drugs.”
(Editor’s note: For related content, see “SNMMI: Study Shows Viability of FAPI PET/CT for Predicting Progressive Pulmonary Fibrosis in Lung Disease Patients,” “Meta-Analysis Assesses Impact of PSMA PET/CT for Staging of Renal Cell Carcinoma” and “Study: PSMA PET/CT May Rule Out csPCa in 93 Percent of PI-RADS 3 Lesions.”)
For more insights from Dr. Cutler, watch the video below.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
